32 Quick summary: Researchers in Spain have discovered that a previously unknown transcription factor called IRF2 acts as a vital pathogenic driver in multiple myeloma, offering a promising new molecular target to combat treatment resistance and frequent patient relapses. The extensive genetic study demonstrates that expression levels of this specific protein can successfully stratify blood cancer patients by their individual prognosis, potentially allowing clinicians to integrate the biomarker into existing classification systems. For healthcare practice and public policy, these foundational findings pave the way for highly personalised oncology treatments and targeted gene therapies that could significantly improve long term survival rates and enhance patient well-being. Researchers in Spain have identified a promising new therapeutic target for multiple myeloma, a blood cancer known for its resistance to treatment and frequent patient relapses. Scientists at the Centre for Applied Medical Research (Cima) and Clínica Universidad de Navarra have uncovered a new molecular mechanism underlying the disease. The study examined which transcription factors, proteins that regulate gene activation, are essential to the development of multiple myeloma. It builds on earlier work by the same team that mapped the complete epigenome of myeloma. “In those studies, we discovered that transcription factors could play a key role in the epigenomic alterations of multiple myeloma. In the study we have just published, we demonstrate the role of IRF2, a transcription factor whose role in this disease was previously unknown and which may become a promising therapeutic target,” said Dr Nahia Gómez-Echarte, a postdoctoral researcher at Cima and first author of the study, published in the journal Blood. Dr Xabier Agirre, principal investigator of the Cima Epigenetics Group and co-director of the study alongside Drs Felipe Prósper and Edurne San José-Enériz, added: “We have also confirmed that its expression is a good biomarker because it allows us to stratify patients based on better or worse prognoses.” The study analysed 230 transcription factors identified using computational tools, narrowing these to 54 factors expressed in myeloma cells. Researchers designed 10 different CRISPR guides for each factor to test whether inhibiting them affected the viability of myeloma cells, identifying 22 factors potentially essential to the cancer’s development. Among these, IRF2 was shown to play key biological roles, including regulating necroptosis (a form of cell death), migration, and cell cycle control in multiple myeloma. Its expression levels also allow for improved patient stratification, distinguishing those with better or worse prognoses. Dr Agirre noted that “Incorporating this biomarker into current multiple myeloma classification systems could improve the ability to predict patients’ response to treatments.” Multiple myeloma affects plasma cells in the bone marrow, causing the overproduction of abnormal proteins that can damage bones, kidneys, and the immune system. Around 6,500 new cases are diagnosed each year in the UK, making it the 19th most common cancer there. While survival rates have improved with modern therapies, many patients still face relapses as the disease develops resistance. The discovery comes as researchers worldwide focus on identifying the molecular drivers of multiple myeloma. Current treatments include chemotherapy, targeted therapies such as proteasome inhibitors, immunomodulatory drugs, and newer options like CAR-T cell therapy, but the disease remains incurable for most patients, underscoring the need for novel therapeutic targets such as IRF2. By linking expression levels of the transcription factor to patient outcomes, clinicians may eventually be able to personalise treatment more effectively, whether by intensifying therapy for higher risk patients or exploring drugs that specifically inhibit IRF2 activity. Transcription factors like IRF2 act as master switches that turn genes on or off, and disrupting these switches could offer a way to halt cancer growth where traditional treatments fail. The study was conducted within the framework of CIBER Cancer (CIBERONC) and received public funding from the Carlos III Health Institute and the Government of Navarre, along with support from private institutions including the Paula and Rodger Riney Foundation. Experts not involved in the research have welcomed the findings as a step forward in developing more precise interventions. Further clinical trials will be needed to develop IRF2-targeted therapies, though the validation of its role through CRISPR screening has strengthened confidence in its relevance. Dr Gómez-Echarte and colleagues noted that IRF2 inhibition impaired cell viability in laboratory models, pointing to its essential function. Its dual role as both a pathogenic driver and prognostic marker makes it particularly valuable for future myeloma management strategies.